Accomplished

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Collaborative

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Enabling

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Innovative

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Focused

To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.

Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.

Our products

Our product portfolio comprises marketed products, which provide an important source of revenue; branded investigational drugs, at different stages of development with partners or by Vectura alone; and generic investigational drugs.

Annual Report

Annual Report and Accounts for Year Ended 31 March 2014

 

In focus

Vectura signs global development and licence agreement with Janssen in asthma/COPD

Chippenham, UK – 6 January 2015: Vectura Group plc (LSE: VEC; "Vectura" or the "Company") today announced that the company has entered into a global development and licence agreement with Janssen Biotech, Inc. ("Janssen") for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will focus initially on the development of a Phase II candidate and has the potential to include additional clinical-stage candidates.

09 Mar 2015

ROTH 27th Annual Conference 2015, California (Vectura presentation 10th March at 4.00pm PST (12.00am GMT – 11th March 2015))

10 Mar 2015

Barclays Global Healthcare Conference, Miami